U.S. Stock Market Midday Update: Kairos Pharma up 140.99%

U.S. Stock Market Midday Update

Kairos Pharma rose 140.99%, with increased trading volume. Based on recent important news:

1. On June 5, Phio Pharmaceuticals received a "Buy" rating from H.C. Wainwright, with a target price set at $14, significantly raised from before, driving the stock price up 12.4%.

2. On June 20, Baicheng Pharmaceuticals unlocked 39.6 million shares, accounting for 36.25% of the total share capital, impacting market liquidity.

3. On July 2, Kangzhong Medical experienced a block trade of 1.49 million shares, affecting market sentiment.

Stocks with High Trading Volume in the Industry

Longevity Health rose 147.68%, with a trading volume of $284 million. Based on recent important news:

1. On July 14, Longevity Health announced a stock-for-stock merger agreement with THPlasma valued at $59 million, with the stock price rising 77% in after-hours trading.

2. On July 14, Longevity Health terminated its deal with 20/20 BioLabs to focus on the merger with THPlasma.

3. On July 14, the merged company is expected to continue trading under the XAGE ticker on NASDAQ, enhancing market confidence.

ProKidney rose 11.10%, with a trading volume of $50.43 million. Based on recent important news:

1. On July 15, ProKidney reached an agreement with the FDA to expedite the approval of its product rilparencel, driving the stock price up over 10%.

2. On July 14, Guggenheim raised ProKidney's target price from $6 to $7, boosting market confidence.

3. On July 15, the FDA confirmed that eGFR slope can serve as an endpoint for biologics license applications, further supporting the stock price increase.

Cyclacel Pharma rose 55.29%, with increased trading volume. Based on recent important news:

1. On June 20, Cyclacel Pharmaceuticals announced a $3 million private placement of convertible preferred stock, leading to a significant increase in stock price.

2. On June 4, the company regained compliance with NASDAQ's minimum bid price requirement, enhancing market confidence.

3. On June 20, a securities purchase agreement was signed, further driving the stock price up.

Stocks with High Market Capitalization in the Industry

AbbVie rose 0.21%, with a market capitalization of $336.1 billion. Based on recent important news:

1. On July 12, AbbVie was considered one of the ideal dividend growth stocks, attracting income and growth-oriented investors, driving the stock price up 0.21%

2. On July 11, policy uncertainty prompted large pharmaceutical companies to lean towards licensing deals, benefiting AbbVie in this context.

3. On July 15, although analysts rated AbbVie as a moderate buy, its dividend attractiveness still supports the stock price